Care for Peripheral Arterial Disease (PAD) at University of Colorado Hospital

Why Choose Treatment for Peripheral Arterial Disease at University of Colorado Hospital?

University of Colorado Hospital is the first hospital in Denver and the Rocky Mountain region to use new minimally invasive treatments for PAD. We have a comprehensive program with doctors who are experts in treating PAD. We also are conducting new research on peripheral arterial disease.

What is Peripheral Arterial Disease?

Peripheral arterial disease (PAD), also called peripheral vascular disease, happens when there is a narrowing of blood vessels outside of your heart. It can limit blood flow to body parts such as the:

If Peripheral arterial disease is not treated, it may get worse over time. It can lead to:

Risk factors for Peripheral arterial disease include:

  • History of coronary artery disease
  • Male gender
  • Diabetes
  • Post-menopause in women
  • High blood pressure (hypertension)
  • High blood lipid (fat) levels (dyslipidemia)
  • Obesity
  • Physical inactivity
  • Smoking

Departments Treating Peripheral Arterial Disease

Cardiac & Vascular Center
Anschutz Medical Campus, Aurora
(720) 848-5300

Peripheral Arterial Disease Research

The doctors and staff in the Cardiac & Vascular Center at University of Colorado Hospital conduct numerous vascular medicine research. This ensures the latest treatments are available for our patients suffering from PAD.

Peripheral Arterial Disease Research Trials

  • Research study on outcomes in patients with a critical restriction of blood flow to the limbs (critical limb ischemia, or CLI)
  • Multicenter clinical research on patterns of PAD in patients with CLI
  • Multicenter Veterans Administration study to examine limb problems and death in patients with severe PAD
  • Phase I clinical trials to test drug treatment of severe calf cramping (claudication) in patients with PAD
  • Studies to assess whether certain medications improve treadmill and walking ability and health-related quality of life (HQL) in patients with intermittent cramping and limping resulting from PAD

Title – Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

Purpose – Phase 2 clinical research study to examine the safety of an experimental gene transfer agent and its ability to stimulate the growth of new blood vessels from existing blood vessels in an attempt to improve the blood flow in the legs of patients with peripheral arterial disease.

Sponsor – Genzyme